Clinical trial NCT02119260: A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
Official title: A Sponsor Un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Oedema, Pulmonary
Keywords: First Time in Human
TRPV4 inhibitor
Heart failure
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2014-04-21
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is the first administration of GSK2798745 in humans. This will be a sponsor un-blinded, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2798745, given as single and repeat oral doses to healthy subjects and stable heart failure (HF) subjects. Approximately 28 healthy subjects will be enrolled in the study cohorts (Cohort 1-3) involving single and repeat dose escalations of GSK2798745, while up to 24 stable heart failure subjects will be enrolled in Cohort 4 involving single and repeat dose administration of GSK2798745, with the dose selected based on data from healthy subject cohorts. This would be followed by enrollment of up to 8 subjects with heart failure in Cohort 5 involving repeat dose administration of GSK2798745. The study duration, including screening and follow-up, is not expected to exceed 17 weeks for subjects in the study (in any cohort).


Eligibility criteria: Inclusion Criteria:

For Healthy Subject Cohorts (1-3):

* Male or female 18-75 years of age inclusive, at the time of signing the informed consent.
* Healthy as determined by a responsible and experienced physician, based on an evaluation including medical history, physical examination, laboratory tests and cardiac evaluation including ECG and echocardiogram. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GSK Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
* Body weight \>=50 kilogram (kg) and Body Mass Index (BMI) within the range 18-32 kilogram/ square meter (kg/m\^2) (inclusive).
* A female subject is eligible to participate if she is of Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, "documented" refers to the outcome of the Investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 milli-International Units per milliliter (mIU/mL) and estradiol \<40 picogram/millilitre (pg/mL) \[\<147 picomoles/liter (pmol/L)\] is confirmatory.
* Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 2 weeks post last dose.
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
* Alanine transaminase (ALT), alkaline phosphatase and bilirubin \<= 1.5x Upper limit of normal (ULN) (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
* Based on averaged QTc values of triplicate ECGs obtained over a brief recording period: QTc \<450 milliseconds (msec); or QTc \<480 msec in subjects with Bundle Branch Block.

For Heart Failure Subjects (Cohorts 4 and 5):

* Established diagnosis of mild or moderate heart failure of any aetiology with symptoms defined as corresponding to the New York Heart Association (NYHA) Class II or III on stable heart failure therapy for at least 1 month and was not hospitalized for HF for the last three months.
* Male or female 18 years or older, age inclusive, at the time of signing the informed consent.
* ALT, alkaline phosphatase and bilirubin \<=1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
* Based on averaged QTc values of triplicate ECGs obtained over a brief recording period: QTc \<450msec; or QTc \<480msec in subjects with Bundle Branch Block.
* Female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, "documented" refers to the outcome of the Investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \>40mIU/mL and estradiol \<40pg/mL (\<147pmol/L) is confirmatory.
* Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 2 weeks post-last dose.
* Body weight \>=50kg and BMI within the range 18-40kg/m\^2 (inclusive).
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 6 months.
* History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of \>21 units for males or \>14 units for females. One unit is equivalent to 8 gram (g) of alcohol: a half-pint (approximately 240mL) of beer, 1 glass (125mL) of wine or 1 (25mL) measure of spirits.
* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator and/or GSK Medical Monitor, contraindicates their participation.
* History of seizure disorder and or stroke within the last 5 years.
* Active ulcer disease or gastrointestinal (GI) bleeding.
* Current smokers (Cohorts 1-4 only).
* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
* A positive pre-study drug/alcohol screen.
* A positive test for human immunodeficiency virus (HIV) antibody.
* A screening cardiac Troponin (cTn) level \>ULN.
* Baseline presence of severe aortic stenosis.
* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
* Left ventricular ejection fraction \<50 percent - (Healthy subjects only).
* Subject who, in the Investigator/designee's judgement, poses a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behaviour and/or any evidence of suicidal ideation on any questionnaires e.g., Type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) in the last 5 years.

For Heart Failure Subjects (Cohort 4):

* History of known primary pulmonary disease requiring current medication or other therapy.
* Orthopnoea of sufficient severity to preclude supine scanning as determined at screening.
* Uncontrolled hypertension (resting systolic blood pressure \[BP\] \> 160 millimeters of mercury \[mmHg\] or resting diastolic BP \> 100 mmHg).
* Resting hypoxia while breathing room air (Peripheral capillary oxygen saturation \[SpO2\] \<88 percent).
* Estimated creatinine clearance (Cockcroft-Gault) \<40 mL/minute.
* Contraindication to magnetic resonance imaging (MRI) contrast agents.
* Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: a. Intracranial aneurysm clips (except Sugita\^®; trademark owned by Mizuho Ikakogyo Co.Ltd. Tokyo) or other metallic objects; b. Intra- orbital metal fragments that have not been removed; c. Pacemakers or other implanted cardiac rhythm management/monitoring devices and non-MR conditional heart valves; d. Inner ear implants; and e. History of claustrophobia.

For Heart Failure Subjects (Cohort 5):

* Uncontrolled hypertension (resting SBP \>160 mmHg or reporting DBP \>100 mmHg).
* Resting hypoxia while breathing room air (SpO2 \<88 percent).

Primary outcomes:
measure: Number of Participants With Vital Sign Values of Potential Clinical Concern in Healthy Participants
timeFrame: Up to 17 Weeks
measure: Number of Participants With Vital Sign Values of Potential Clinical Concern in Stable Heart Failure Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Concern in Healthy Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Concern in Stable Heart Failure Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Clinical Chemistry Laboratory Values of Potential Clinical Concern in Healthy Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Clinical Chemistry Laboratory Values of Potential Clinical Concern in Stable Heart Failure Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Hematology Parameter Laboratory Values of Potential Clinical Concern in Healthy Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Hematology Parameter Laboratory Values of Potential Clinical Concern in Stable Heart Failure Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Abnormal Routine Urinalysis in Healthy Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Abnormal Routine Urinalysis in Stable Heart Failure Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) in Healthy Participants
timeFrame: Up to 17 weeks
measure: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) in Stable Heart Failure Participants
timeFrame: Up to 17 weeks
Secondary outcomes:
measure: Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC[0-inf]) Following Single and Repeat Doses of GSK2798745 in Healthy Subjects
timeFrame: Day 1
measure: Maximum Observed Plasma Concentration (Cmax) Following Single and Repeat Dose Administration of GSK2798745 in Healthy Participants
timeFrame: Day 1 (Cohort 1,2,3) and Day 14 (Cohort 3)
measure: Time to Occurrence of Cmax (Tmax) Following Single and Repeat Doses of GSK2798745 in Healthy Participants
timeFrame: Day 1 (Cohort 1,2,3) and Day 14 (Cohort 3)
measure: Maximum Observed Plasma Concentration (Cmax) Following Single and Repeat Dose Administration of GSK2798745 in Stable Heart Failure Participants
timeFrame: Day 1 and Day 7
measure: Area Under the Concentration-time Curve From Pre-dose to 24 Hours Post-dose (AUC [0-24]) Following Single and Repeat Doses of GSK2798745 in Stable Heart Failure Participants
timeFrame: Day 1 and Day 7
Other outcomes:
Locations:
city: Cambridge
country: United Kingdom
facility: GSK Investigational Site
city: London
country: United Kingdom
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Goyal N, Skrdla P, Schroyer R, Kumar S, Fernando D, Oughton A, Norton N, Sprecher DL, Cheriyan J. Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects. Am J Cardiovasc Drugs. 2019 Jun;19(3):335-342. doi: 10.1007/s40256-018-00320-6.